Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Lung
Published in: Lung 1/2008

01-02-2008

Preclinical Assessment of Novel Therapeutics on the Cough Reflex: Cannabinoid Agonists as Potential Antitussives

Author: Maria G. Belvisi

Published in: Lung | Special Issue 1/2008

Login to get access

Abstract

Cough, a reflex defense mechanism, is a common symptom of many airway inflammatory diseases. At present there are no satisfactory treatments for cough that have an acceptable side effect profile. Recent data have described the inhibitory effect of selective cannabinoid CB2 receptor agonists on sensory nerve activity in vitro and the cough reflex in a guinea pig model. CB2 receptor expression is limited in the central nervous system (CNS) and hence the development of selective agonists may provide a new therapeutic strategy for treatment of cough devoid of the CNS-mediated side effects that are normally associated with nonselective cannabinoid agonists.
Literature
1.
Widdicombe JG (1999) Advances in understanding and treatment of cough. Monaldi Arch Chest Dis 54:275–279PubMed
2.
Shroeder K, Fahey T (2002) Systematic review of randomised controlled trials of over the counter cough medicines for acute cough in adults. BMJ 324:1–6
3.
Karlsson JA, Fuller RW (1999) Pharmacological regulation of the cough reflex – from experimental models to antitussive effects in man. Pulm Pharmacol Ther 12:215–228PubMedCrossRef
4.
Moreaux B, Beerens D, Gustin P (1999) Development of a cough induction test in pigs: effects of SR 48968 and enalapril. J Vet Pharmacol Ther 22:387–389PubMedCrossRef
5.
Forsberg K, Karlsson JA, Theodorsen E, Lundberg JM, Persson CGA (1988) Cough and bronchoconstriction mediated by capsaicin-sensitive sensory neurons in guinea pigs. Pulm Pharmacol 1:33–39PubMedCrossRef
6.
Fox AJ, Barnes PJ, Urban L, Dray A (1993) An in vivo study of the properties of single vagal afferents innervating guinea pig airways. J Physiol 469:21–35PubMed
7.
8.
Fox AJ, Lalloo UG, Belvisi MG, Bernareggi M, Chung KF, Barnes PJ (1996) Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough. Nat Med 2:814–817PubMedCrossRef
9.
Fox AJ, Barnes PJ, Venkatesan P, Belvisi MG (1997) Activation of large conductance potassium channels inhibits the afferent and efferent function of airway sensory nerves in the guinea pig. J Clin Invest 99:513–519PubMedCrossRef
10.
Lalloo UG, Fox AJ, Belvisi M, Chung K, Barnes PJ (1995) Capsazepine inhibits cough induced by capsaicin and citric acid but not by hypertonic saline in guinea pigs. J Appl Physiol 79:1082–1087PubMed
11.
Trevisani M, Milan A, Gatti R, Zanasi A, Harrison S, Fontana G, Morice AH, Geppetti P (2004) Antitussive activity of iodo-resiniferatoxin in guinea pigs. Thorax 59(9):769–772PubMedCrossRef
12.
Liu Q, Fujimura M, Tachibana H, Myou S, Kasahara K, Yasui M (2001) Characterization of increased cough sensitivity after antigen challenge in guinea pigs. Clin Exp Allergy 31(3):474–484PubMedCrossRef
13.
Oribe Y, Fujimura M, Kita T, Katayama N, Nishitsuji M, Hara J, Myou S, Nakao S (2005) Attenuating effect of H+K+ATPase inhibitors on airway cough hypersensitivity induced by allergic airway inflammation in guinea-pigs. Clin Exp Allergy 35(3):262–267PubMedCrossRef
14.
Lewis CA, Ambrose C, Banner K, Battram C, Butler K, Giddings J, Mok J, Nasra J, Winny C, Poll C (2007) Animal models of cough: literature review and presentation of a novel cigarette smoke-enhanced cough model in the guinea-pig. Pulm Pharmacol Ther 20(4):325–333PubMedCrossRef
15.
Nasra J, Birrell MA, Poll C, Lewis CA, Belvisi MG (2007) Distinct patterns of response to tussive agents in a guinea-pig model of cough: effect of cigarette smoke exposure. Am J Respir Crit Care Med 41:A667
16.
Porter AC, Felder CC (2001) The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 90:45–60PubMedCrossRef
17.
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561–564PubMedCrossRef
18.
Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterisation of a peripheral receptor for cannabinoids. Nature 365:61–65PubMedCrossRef
19.
Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder C, Glass M, Zimmer A (2000) Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoiod CB2 receptor. Eur J Parmacol 396:141–149CrossRef
20.
Griffin G, Fernando SR, Ross RA, McKay NG, Ashford MLJ, Shire D, Huffman JW, Yu S, Lainton JAH, Pertwee RG (1997) Evidence for the presence of CB2 like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol 339:53–61PubMedCrossRef
21.
Galiegue S, Mary S, Marchland J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54–61PubMedCrossRef
22.
Richardson JD, Aanonsen L, Hargreaves KM (1998) Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 345:145–153PubMedCrossRef
23.
Clayton N, Marshall FH, Bountra C, O’Shaughnessy (2002) CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 96:253–260
24.
Malan TP, Ibrahim MM, Vanderah TW, Makriyannis A, Porreca F (2002) Inhibition of pain responses by activation of CB2 cannabinoid receptors. Chem Physics Lipids 121:191–200CrossRef
25.
Patel HJ, Birrell MA, Crispino N, Hele DJ, Venkatesan P, Barnes PJ, Yacoub MH, Belvisi MG (2003) Inhibition of guinea pig and human sensory nerve activity and the cough reflex in guinea pigs by cannabinoid (CB2) receptor activation. Br J Pharmacol 140:261–268PubMedCrossRef
26.
Calignano A, Katona I, Desarnaud F, Giuffrida A, La Rana G, Mackie K, Freund TF, Piomelli D (2000) Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature 408:96–101PubMedCrossRef
27.
Morita K, Kamei J (2003) Antitussive activity of WIN 55212-2, a cannabinoid receptor agonist. Eur J Pharmacol 427:269–272CrossRef
Metadata
Title
Preclinical Assessment of Novel Therapeutics on the Cough Reflex: Cannabinoid Agonists as Potential Antitussives
Author
Maria G. Belvisi
Publication date
01-02-2008
Publisher
Springer-Verlag
Published in
Lung / Issue Special Issue 1/2008
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-007-9028-8

Other articles of this Special Issue 1/2008

Lung 1/2008 Go to the issue

OriginalPaper

Basic Mechanisms of Cough: Current Understanding and Remaining Questions

OriginalPaper

Quality of Life and Psychosocial Aspects of Cough

OriginalPaper

Before We Get Started: What Is a Cough?

OriginalPaper

Rebuttal: Cough Is an Expiratory Sound

OriginalPaper

World Trade Center Cough Syndrome and Its Treatment

OriginalPaper

Erdosteine: Antitussive and Anti-inflammatory Effects
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits